Leerink Partners Forecasts Strong Price Appreciation for Bruker (NASDAQ:BRKR) Stock

Posted by Geri Gentry on Jul 7th, 2026

Bruker (NASDAQ:BRKR – Get Free Report) had its price objective increased by investment analysts at Leerink Partners from $60.00 to $70.00 in a report issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Leerink Partners’ target price points to a potential upside of 19.86% from the company’s previous close.

A number of other research firms have also weighed in on BRKR. Barclays upped their target price on Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Stifel Nicolaus set a $45.00 price objective on Bruker in a research note on Friday, May 8th. Citigroup upped their price objective on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. Finally, TD Cowen lifted their target price on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $55.64.

View Our Latest Research Report on Bruker

Bruker Stock Down 4.8%

Shares of NASDAQ:BRKR traded down $2.94 during trading hours on Tuesday, hitting $58.40. The company’s stock had a trading volume of 1,070,299 shares, compared to its average volume of 2,434,989. Bruker has a 52 week low of $28.53 and a 52 week high of $64.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The company has a market capitalization of $8.89 billion, a price-to-earnings ratio of -243.83, a P/E/G ratio of 1.97 and a beta of 1.29. The firm’s fifty day moving average price is $51.07 and its 200 day moving average price is $45.13.

Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The firm had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the prior year, the company earned $0.47 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker will post 2.12 EPS for the current year.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aquatic Capital Management LLC raised its position in shares of Bruker by 120.3% in the 3rd quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after purchasing an additional 190,883 shares during the last quarter. Callodine Capital Management LP acquired a new position in Bruker during the 3rd quarter valued at approximately $1,105,000. Thrivent Financial for Lutherans raised its holdings in shares of Bruker by 561.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after buying an additional 152,603 shares during the last quarter. Natixis Advisors LLC lifted its stake in shares of Bruker by 31.1% during the third quarter. Natixis Advisors LLC now owns 627,672 shares of the medical research company’s stock worth $20,394,000 after buying an additional 148,915 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Bruker by 134.5% during the fourth quarter. SG Americas Securities LLC now owns 99,173 shares of the medical research company’s stock worth $4,672,000 after buying an additional 56,880 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bruker

(Get Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.